The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRLM.L Regulatory News (RLM)

  • There is currently no data for RLM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Change of Adviser

12 Nov 2009 07:00

RNS Number : 3829C
PuriCore Plc
12 November 2009
 



PuriCore plc

Appointment of Financial Adviser and Corporate Broker

MALVERN, PENNSYLVANIA, AND STAFFORD, UK, 12 November 2009 - PuriCore (LSE: PURI), the life sciences company focused on developing and commercialising proprietary, green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment, today announces the appointment of Piper Jaffray Ltd. as its Financial Adviser and Corporate Broker to the Company with immediate effect.

Enquiries:

Ben Brewerton

Greg Bosch, CEO

Jamie Adams

Susan Quigley

Darren Weiss, CFO

Michael Covington

Financial Dynamics

PuriCore

Piper Jaffray Ltd.

+44 (0) 20 7831 3113

+1 484 321 2700

+44 (0) 20 3142 8700

About PuriCore

PuriCore plc (LSE: PURI) is a life sciences company focused on developing and commercialising proprietary green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment. PuriCore's patented, proprietary technology mimics the human body's production of the natural antimicrobial hypochlorous acid, offering a safe and non-hazardous approach to disinfection and sanitisation. The Company's products are used in a broad range of markets that depend upon controlling contamination, including food retail and foodservice, medical device disinfection, and wound care. Hypochlorous acid is proven to be safe, environmentally friendly, and fast acting against a broad range of infectious pathogens, including major public health threats of C.difficileE.coli, HIV, Human and Animal Influenza (including H1N1 and H5N1), Legionella, MRSAM.tuberculosis, Norovirus, and Salmonella. PuriCore is headquartered in MalvernPennsylvania, with offices in Stafford and ClevedonUK

To receive additional information on PuriCore, please visit our website at www.puricore.com, which does not form part of this press release.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
APPEAEFFFFENFAE
Date   Source Headline
21st Nov 20177:00 amRNSRealm: Preclinical Data on PR022 Published
17th Nov 20177:00 amRNSDirectorate Change
2nd Nov 20177:00 amRNSRealm Therapeutics to Present at BIO-Europe® 2017
30th Oct 20177:00 amRNSRealm Presents Data at ACAAI Scientific Meeting
18th Oct 20177:00 amRNSHolding(s) in Company
18th Oct 20177:00 amRNSBlock Listing Application
17th Oct 20176:28 pmRNSHolding(s) in Company
16th Oct 20173:39 pmRNSHolding(s) in Company
16th Oct 20177:00 amRNSRealm Therapeutics to speak at BIO Investor Forum
13th Oct 20172:20 pmRNSHolding(s) in Company
13th Oct 20172:17 pmRNSHolding(s) in Company
12th Oct 20175:48 pmRNSHolding(s) in Company
12th Oct 20173:07 pmRNSRealm Therapeutics: Completion of £19.3m Placing
12th Oct 201711:04 amRNSHolding(s) in Company
12th Oct 201710:58 amRNSHolding(s) in Company
9th Oct 201711:35 amRNSResult of General Meeting
22nd Sep 20177:00 amRNSProposed Placing to raise £19.3 million
22nd Sep 20177:00 amRNSInterim Results
21st Sep 20176:01 pmRNSProposed Placing to raise £19.3 million
21st Sep 20176:00 pmRNSInterim Results
11th Sep 20177:00 amRNSFDA Permits PR013 to Proceed to Phase II Trial
7th Sep 20177:00 amRNSConference Presentation
18th Aug 20177:00 amRNSBlock listing Interim Review
2nd Aug 20177:00 amRNSSubmission of Investigational New Drug Application
6th Jul 20177:00 amRNSPresentation at World Congress on Inflammation
14th Jun 20177:09 amRNSPresentation at 2017 Marcum Microcap Conference
6th Jun 201711:05 amRNSResult of AGM
11th May 201712:21 pmRNSNotice of AGM
23rd Mar 20172:57 pmRNSAnnual Report and Accounts Available
23rd Mar 20177:00 amRNSFinal Results and Business Update
6th Mar 20177:00 amRNSConference Presentation
28th Feb 20177:00 amRNSFDA permits PR022 to Proceed to Phase 2 Trial
20th Feb 20177:00 amRNSBlock listing Interim Review
13th Feb 20177:00 amRNSPresentation at BIO CEO & Investor Conference
30th Jan 20177:00 amRNSResearch Update - Submission of first IND
5th Jan 20177:00 amRNSConference Presentations
4th Jan 20177:00 amRNSGrant of Options
21st Dec 20167:00 amRNSPDMR dealing
16th Dec 20167:00 amRNSIvan Gergel appointed as Non-Executive Director
7th Dec 20167:00 amRNSChange of name to Realm Therapeutics
18th Nov 20167:00 amRNSGrant of Options
17th Nov 20167:00 amRNSHolding(s) in Company
16th Nov 20167:00 amRNSDevelopment Programmes Update & Company Renaming
10th Oct 20167:00 amRNSCompletion of Supermarket Retail Business Disposal
7th Oct 20165:52 pmRNSCompletion of Supermarket Retail Business Disposal
6th Oct 201611:43 amRNSResult of General Meeting
23rd Sep 20162:47 pmRNSDirector/PDMR Dealing
22nd Sep 20162:15 pmRNSGrant of Options
20th Sep 20167:00 amRNSProposed Disposal of Supermarket Retail Business
20th Sep 20167:00 amRNSHalf-year Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.